Key result
Bone marrow involvement detected by bone marrow biopsy, but not by PET/CT, independently predicted shorter progression-free survival in DLBCL patients treated with first-line R-CHOP/21.
Why the study?
Does bone marrow biopsy compared to PET/CT better predict progression-free survival in patients with diffuse large B-cell lymphoma?
Cohort (n=268)
Yes
Does bone marrow biopsy compared to PET/CT better predict progression-free survival in patients with diffuse large B-cell lymphoma?
Answers are grounded in this paper and cite their sources.
Bone marrow biopsy is superior to PET/CT in predicting progression-free survival in DLBCL patients treated with uniform first-line chemotherapy.
Several studies have reported uneven results when evaluating the prognostic value of bone marrow biopsy (BMB) and PET/CT as part of the staging of diffuse large B-cell lymphoma (DLBCL). The heterogeneity of the inclusion criteria and not taking into account selection and collinearity biases in the analysis models might explain part of these discrepancies. To address this issue we have carried a retrospective multicenter study including 268 DLBCL patients with a BMB and a PET/CT available at diagnosis where we estimated both the prognosis impact and the diagnostic accuracy of each technique. Only patients treated with R-CHOP/21 as first line (n = 203) were included in the survival analysis. With a median follow-up of 25 months the estimated 3-year progression-free survival (PFS) and overall survival (OS) were 76.3% and 82.7% respectively. In a multivariate analysis designed to avoid a collinearity bias with IPI categories, BMB-BMI [bone marrow involvement](+) (HR: 3.6) and ECOG PS > 1 (HR: 2.9) were independently associated with a shorter PFS and three factors, age >60 years old (HR: 2.4), ECOG PS >1 (HR: 2.4), and abnormally elevated B2-microglobulin levels (HR: 2.2) were independently associated with a shorter OS. In our DLBCL cohort, treated with a uniform first-line chemotherapy regimen, BMI by BMB complemented performance status in predicting those patients with a higher risk for relapse or progression. In this cohort BMI by PET/CT could not independently predict a shorter PFS and/or OS.
No takes yet. Share an insight, caveat, or question.
Chen‐Liang et al. (2017) conducted a cohort in Diffuse large B-cell lymphoma (DLBCL) (n=268). Bone marrow involvement by bone marrow biopsy vs. Bone marrow involvement by PET/CT was evaluated on Progression-free survival (PFS) (HR 3.6). Bone marrow involvement detected by bone marrow biopsy, but not by PET/CT, independently predicted shorter progression-free survival in DLBCL patients treated with first-line R-CHOP/21.
Synapse has enriched 10 related papers. Consider them for comparative context: